Onco Wiki / Enfermedad

Síndromes mielodisplásicos: Riesgo superior (IPSS-R alto/muy alto; incluye MDS-EB)

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDDIS-MDS-HR
TipoEnfermedad
Aliaces
HR-MDSSMD de mayor riesgoMDS con exceso de blastosMDS-EBMDS-HRSíndromes mielodisplásicos: mayor riesgoRAEB (Legado de la FAB)Мієлодиспластичні синдроми, високий ризик (IPSS-R високий / дуже високий; включає MDS-EB)
Situaciónreviewed 2026-04-25 | pending_clinical_signoff
EnfermedadesNinguna declarada
FuentesSRC-ESMO-MDS-2021 SRC-IPSS-M-BERNARD-2022 SRC-NCCN-AML-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Fuente YAML

icd_o_3_morphology9983/3
icd_o_3_topography["C42.1"]
icd_10D46.2
who_classificationMyelodysplastic neoplasms with increased blasts (MDS-IB1, MDS-IB2 per WHO 5th ed.) — higher-risk subgroup

Capacidades

Notas

Separated from MDS-LR because therapeutic intent (disease modification + transplant bridge) differs from cytopenia management. WHO 5th ed. reclassifies the older "MDS-EB" / "RAEB" terminology to MDS-IB1 (5-9% blasts) and MDS-IB2 (10-19% blasts). TP53-mutated MDS is its own WHO entity with poor HMA + alloHCT outcomes (active research question; no consensus best regimen). STUB — requires clinical co-lead signoff before publication. Myeloid expansion (heme).

Utilizado por

Relevancia terapéutica

Algoritmos

Enfermedad

Indicación

Cuestionarios

Señal de alerta

Fuentes